Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy

被引:38
|
作者
Luveta, Jocelyn [1 ,2 ]
Parks, Ruth M. [3 ]
Heery, David M. [2 ]
Cheung, Kwok-Leung [3 ]
Johnston, Simon J. [1 ,2 ]
机构
[1] Univ Nottingham, Div Canc & Stem Cells, Nottingham Breast Canc Res Ctr, Sch Med, Nottingham, England
[2] Univ Nottingham, Gene Regulat & RNA Biol, Sch Pharm, Nottingham, England
[3] Univ Nottingham, Div Med Sci & Grad Entry Med, Nottingham Breast Canc Res Ctr, Sch Med, Nottingham, England
关键词
Aromatase inhibitors; Breast cancer; Endocrine therapy; Histology; Immunotherapy; Invasive lobular carcinoma; Molecular biology; Surgical management; Tamoxifen; Targeted therapy; COMPREHENSIVE MOLECULAR PORTRAITS; E-CADHERIN; ENDOCRINE-THERAPY; NEOADJUVANT CHEMOTHERAPY; IMAGING FEATURES; GENE-EXPRESSION; INCIDENCE RATES; ESR1; MUTATIONS; CARCINOMA; ESTROGEN;
D O I
10.1007/s40487-019-00105-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Invasive lobular carcinoma comprises 10-15% of all breast cancers and is increasingly recognised as a distinct and understudied disease compared with the predominant histological subtype, invasive ductal carcinoma. Hallmarks of invasive lobular carcinoma include E-cadherin loss, leading to discohesive morphology with cells proliferating in single-file strands and oestrogen receptor positivity, with favourable response to endocrine therapy. This review summarises the distinct histological and molecular features of invasive lobular carcinoma with focus on diagnostic challenges and the impact on surgical management and medical therapy. Emphasis is placed on recent advances in our understanding of the unique molecular biology of lobular breast cancer and how this is optimising our therapy approach in the clinic.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 50 条
  • [1] Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy
    Jocelyn Luveta
    Ruth M. Parks
    David M. Heery
    Kwok-Leung Cheung
    Simon J. Johnston
    Oncology and Therapy, 2020, 8 : 1 - 11
  • [2] BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
    Walsh, Louise
    Haley, Kathryn E.
    Moran, Bruce
    Mooney, Brian
    Tarrant, Finbarr
    Madden, Stephen F.
    Di Grande, Alessandra
    Fan, Yue
    Das, Sudipto
    Rueda, Oscar M.
    Dowling, Catriona M.
    Vareslija, Damir
    Chin, Suet-Feung
    Linn, Sabine
    Young, Leonie S.
    Jirstrom, Karin
    Crown, John P.
    Bernards, Rene
    Caldas, Carlos
    Gallagher, William M.
    O'Connor, Darran P.
    Chonghaile, Triona Ni
    CLINICAL CANCER RESEARCH, 2019, 25 (23) : 7139 - 7150
  • [3] A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
    Nardone, Agostina
    Qiu, Xintao
    Spisak, Sandor
    Nagy, Zsuzsanna
    Feiglin, Ariel
    Feit, Avery
    Feit, Gabriela Cohen
    Xie, Yingtian
    Font-Tello, Alba
    Guarducci, Cristina
    Hermida-Prado, Francisco
    Syamala, Sudeepa
    Lim, Klothilda
    Gomez, Miguel Munoz
    Pun, Matthew
    Cornwell, MacIntosh
    Liu, Weihan
    Ors, Aysegul
    Mohammed, Hisham
    Cejas, Paloma
    Brock, Jane B.
    Freedman, Matthew L.
    Winer, Eric P.
    Fu, Xiaoyong
    Schiff, Rachel
    Long, Henry W.
    Filho, Otto Metzger
    Jeselsohn, Rinath
    CANCER RESEARCH, 2022, 82 (20) : 3673 - 3686
  • [4] Prognostic Implications of Invasive Lobular Breast Cancer
    Brouckaert, O.
    Laenen, A.
    Wildiers, H.
    Leunen, K.
    Amant, F.
    Smeets, A.
    Van Limbergen, E.
    Floris, G.
    Christiaens, M. R.
    Neven, P.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S142 - S142
  • [5] Combination of BET and FGFR inhibition as a rational therapeutic strategy for invasive lobular breast cancer
    O'Connor, Darran P.
    Walsh, Louise
    Haley, Kathryn
    Moran, Bruce
    Mooney, Brian
    Madden, Stephen
    Das, Sudipto
    Rueda, Oscar
    Dowling, Catriona
    Vareslija, Damir
    Chin, Suet-Feung
    Linn, Sabine
    Young, Leonie
    Jirstrom, Karin
    Crown, John P.
    Bernards, Rene
    Caldas, Carlos
    Gallagher, William M.
    Chonghaile, Triona Ni
    CANCER RESEARCH, 2020, 80 (04)
  • [6] Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications
    Barroso-Sousa, Romualdo
    Metzger-Filho, Otto
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (04) : 261 - 266
  • [7] Lobular neoplasms and invasive lobular breast cancer
    Sinn, H. -P.
    Helmchen, B.
    Heil, J.
    Aulmann, S.
    PATHOLOGE, 2014, 35 (01): : 45 - 53
  • [8] Lobular carcinoma in situ and invasive lobular cancer of the breast
    Cocquyt, V
    Van Belle, S
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2005, 17 (01) : 55 - 60
  • [9] TUBULO-LOBULAR INVASIVE BREAST-CANCER - VARIANT OF LOBULAR INVASIVE CANCER
    FISHER, ER
    GREGORIO, RM
    REDMOND, C
    FISHER, B
    HUMAN PATHOLOGY, 1977, 8 (06) : 679 - 683
  • [10] Invasive Lobular Breast Cancer - No Increased Risk of Contralateral Disease.
    Langlands, F.
    Horgan, K.
    Kearins, O.
    Burns, R.
    Dodwell, D.
    CANCER RESEARCH, 2011, 71